Tamera Thoener
Family · Nashville, TNNPI 1194198218
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $165,239 of the $254,328 with a category attached, or 65.0%. Amgen accounts for 87.7% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $104,875, more than ten times the $7,444 reported in 2021. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 666 payments — averaging $381.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$223K
- AbbVie$23K
- Merz North America, Inc.$4K
- Johnson & Johnson$942
- Bayer$561
- Biohaven Pharmaceuticals, Inc.$490
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$165,23965%
- Travel & lodging$75,72330%
- Food & beverage$13,1905%
- Education$1760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 416 | $223,069 |
| AbbVie(2 entities) | 125 | $23,315 |
| Merz North America, Inc. | 25 | $3,659 |
| Johnson & Johnson(2 entities) | 18 | $942 |
| Bayer | 11 | $561 |
| Biohaven Pharmaceuticals, Inc. | 12 | $490 |
| Novo Nordisk | 11 | $447 |
| Lilly USA, LLC | 10 | $355 |
| AstraZeneca | 9 | $277 |
| Merz Pharmaceuticals, LLC | 1 | $143 |
| Axsome Therapeutics, Inc. | 3 | $138 |
| Teva Pharmaceuticals USA, Inc. | 1 | $136 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Akcea Therapeutics, Inc. | 1 | $117 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $114 |
| Exact Sciences | 5 | $106 |
| Lundbeck LLC | 3 | $66 |
| IBSA Pharma Inc. | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Pfizer | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Janssen Scientific Affairs, LLC | 1 | $26 |
| Medtronic | 1 | $23 |
| UCB, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$254,328 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 32 | $38,333 |
| OzempicSemaglutide | 27 | $33,516 |
| VraylarCariprazine Hcl | 11 | $15,438 |
| Nebivolol Hcl | 17 | $1,986 |
| Vilazodone Hcl | 15 | $1,322 |
| Liothyronine Sodium | 28 | $815 |
| Hydroxychloroquine Sulfate | 12 | $539 |
| Olmesartan Medoxomil | 26 | $507 |
| Methylphenidate Hcl | 19 | $477 |
| Gabapentin | 26 | $475 |
| Estradiol | 12 | $373 |
| Atorvastatin Calcium | 17 | $333 |
| Tramadol Hcl | 18 | $267 |
| Ondansetron OdtOndansetron | 12 | $240 |
| Famotidine | 13 | $199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $355 | $38,33332 claims |
| Novo NordiskOzempic | $447 | $33,51627 claims |
| AbbVieVraylar | $23,315 | $15,43811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Nashville
- Jennifer WilliamsNashville$213K
- Lori LankfordNashville$148K
- Melissa RikalNashville$144K
- Nicole DelliseNashville$67K
- Lesley BallanceNashville$63K
- Jeffrey WoodsNashville$38K
- Courtney HavillNashville$35K
- Collette UtleyNashville$28K
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.